Policy | April 01, 2024
Venus Remedies receives Rs. 2.50 crore under PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)